EPS Bio Technology Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für EPS Bio Technology zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 20.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)
Apr 16
Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?
Mar 20Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative
Feb 22Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?
Feb 01
Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?
Jan 04Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?
Dec 14We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential
Nov 23In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EPS Bio Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 470 | 21 | 46 | 55 | N/A |
| 9/30/2023 | 424 | 20 | 47 | 63 | N/A |
| 6/30/2023 | 454 | 24 | 25 | 34 | N/A |
| 3/31/2023 | 442 | 25 | -27 | -14 | N/A |
| 12/31/2022 | 463 | 25 | -10 | 5 | N/A |
| 9/30/2022 | 506 | 36 | 4 | 14 | N/A |
| 6/30/2022 | 485 | 25 | 21 | 35 | N/A |
| 3/31/2022 | 504 | 26 | 41 | 53 | N/A |
| 12/31/2021 | 480 | 19 | 20 | 32 | N/A |
| 9/30/2021 | 451 | 7 | -21 | -10 | N/A |
| 6/30/2021 | 435 | 15 | -2 | 8 | N/A |
| 3/31/2021 | 459 | 22 | 38 | 47 | N/A |
| 12/31/2020 | 478 | 32 | 73 | 80 | N/A |
| 9/30/2020 | 497 | 34 | 114 | 124 | N/A |
| 6/30/2020 | 489 | 28 | 77 | 91 | N/A |
| 3/31/2020 | 466 | 19 | 40 | 55 | N/A |
| 12/31/2019 | 459 | 18 | 5 | 22 | N/A |
| 9/30/2019 | 437 | 33 | 1 | 20 | N/A |
| 6/30/2019 | 443 | 31 | -2 | 13 | N/A |
| 3/31/2019 | 445 | 41 | 23 | 37 | N/A |
| 12/31/2018 | 414 | 16 | -3 | 13 | N/A |
| 9/30/2018 | 431 | 13 | -3 | 9 | N/A |
| 6/30/2018 | 404 | 9 | 1 | 12 | N/A |
| 3/31/2018 | 390 | -12 | 1 | 15 | N/A |
| 12/31/2017 | 420 | 3 | 29 | 42 | N/A |
| 9/30/2017 | 434 | 2 | N/A | 15 | N/A |
| 6/30/2017 | 453 | 4 | N/A | 34 | N/A |
| 3/31/2017 | 466 | 27 | N/A | 58 | N/A |
| 12/31/2016 | 467 | 29 | N/A | 41 | N/A |
| 9/30/2016 | 420 | 18 | N/A | 33 | N/A |
| 6/30/2016 | 426 | 33 | N/A | 41 | N/A |
| 3/31/2016 | 416 | 24 | N/A | 33 | N/A |
| 12/31/2015 | 425 | 37 | N/A | 57 | N/A |
| 9/30/2015 | 426 | 29 | N/A | 83 | N/A |
| 6/30/2015 | 419 | 7 | N/A | 94 | N/A |
| 3/31/2015 | 372 | -13 | N/A | 44 | N/A |
| 12/31/2014 | 324 | -33 | N/A | -6 | N/A |
| 9/30/2014 | 339 | -26 | N/A | -25 | N/A |
| 6/30/2014 | 353 | -18 | N/A | -45 | N/A |
| 3/31/2014 | 369 | -4 | N/A | 0 | N/A |
| 12/31/2013 | 384 | 9 | N/A | 46 | N/A |
| 9/30/2013 | 363 | 12 | N/A | 44 | N/A |
| 6/30/2013 | 343 | 14 | N/A | 42 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 4183 über der Sparquote liegt (0.8%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 4183 schneller wachsen werden als der Markt TW
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 4183 in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 4183 schneller wachsen werden als der Markt von TW.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 4183 schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 4183 in 3 Jahren voraussichtlich hoch sein wird